New IBD drug takes first step: safety check in healthy volunteers
NCT ID NCT07423000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called PVT401 in 36 healthy volunteers to see if it is safe and how the body handles it. Participants receive either the drug or a placebo by IV, either as a single dose or multiple doses over five weeks. The goal is to gather safety data before testing the drug in people with inflammatory bowel disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd
RECRUITINGMelbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame inflammatory bowel disease? early safety trial begins
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Could early lipid screening in High-Risk kids prevent future heart attacks?
- Two-Drug cocktail aims to tame stubborn Crohn's disease
- Dutch hospital data reveals hidden patterns in IBD treatment
- Acupuncture points may signal hidden disease activity